Very important practical points in the #ADCs era. More data is needed to learn the safest way of incorporating brain XRT with ADCs. #bcsm

1/8 #TumorBoardTuesday : Time for wrap up!

HER2 Low= molecular entity w new tx options, esp 🗝️ in #TNBC . Margaret Gatti-Mays MD MPH FACP & Nerea Lopetegui-Lia, MD discuss how changes practice in HER2 low #mBC
-- NGS
-- Germline NGS
-- HER2 status guides 2L tx

👇to hear from the experts on their practice

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin: METALLICA

🔍Normoglycemic pts (Cohort A) and prediabetic pts (B)

G3-4 HG (first 8 weeks)
Cohort A➡️2.1%
Cohort B➡️15%

Prophylactic metformin✅️

OncoAlert

Nice to see some RW data regarding SG activity in pts with brain mets. OncoAlert #bcsm

In response to #Tdxd activity in breast cancer across almost all IHC levels, a better, more quantitative scoring system for HER2 is urgently needed. #bcms #onctwitter #her2

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

OncoAlert FDA Oncology

fda.gov/drugs/resource…

#TILs : not only prognostic in TNBC. In a biomarker analysis of TRAIN2, among 389 patients with stage II-III HER2+ BC receiving neoadjuvant chemo + dual HER2 blockade, 13% had high TILs (≥60%) and experienced a 3-year iDFS of 100% (vs 92% if TILs <60%). nature.com/articles/s4152…

The Lancet Breast Cancer Commission

💥A comprehensive roadmap consisting of six themes has been developed by experts to address the issues of breast cancer👇

💥Prevent
💥Personalise
💥Include
💥Collaboration
💥Identify
💥Communicate

OncoAlert
thelancet.com/journals/lance…

Combinatorial strategies to target RAS-driven cancers

📌We can now target what was once thought untargeted, the RAS. However, we still have a long way to go.
A great review on combination strategies👇

OncoAlert
nature.com/articles/s4156…

Here's the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 8th-14th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancer Research

Amazing resource! Single cell atlas of breast cancer - can’t wait to check this out.

Congratulations to Isaac Chan, MD, PhD lab & collaborators incl Sangeetha Reddy Heather McArthur, MD, MPH Christine Hodgdon Evanthia Roussos Torres, MD, PhD UTSW Simmons Cancer Center !

#bcsm OncoAlert

Important work looking at #TNBC subtypes and IHC surrogates for #GEP . Differences in prognosis and immune modulation. One step further into #PrecisionMedicine in #TNBC . #bcsm OncoAlert #MedX #MedTwitter

New actionable #genomic alteration on serial #ctDNA testing in #MBC . This work highlights the potential clinical utility of repeating ctDNA on progression. OncoAlert #bcsm #onctwitter #medX #MedTwitter

rdcu.be/dEDUg

The weekly newsletter from OncoAlert with Gil Morgan, MD's voice👇

Another piece of evidence supporting treating most ER low tumors as phenotypically triple negative. #TNBC #bcsm #MedX #MedTwitter

A negative trial of adding #PARPi to neo-adj chemo in BRCA-WT #TNBC .

Latest Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center

#AACR24 AACR
👇🏾See this piece on #ctDNA #LiquidBiopsies published Cancer Today.

🩸Liquid biopsies are here to stay.

Going beyond prognostication to being integral/predictive biomarkers.

OncoAlert

📌cancertodaymag.org/fall-2023/the-…

A great reminder that this year's early drugs are the standard drugs in 5-10 years.

The progress in oncology is too fast to dismiss the role of clinical trials!!!!

The DESTINY-Pantumor02 trial, which led to the agnostic approval of T-DXd, used for enrollment the guidelines for GASTROESOPHAGEAL cancer! More info in the below 🧵 by Busem Binboga Kurt 👇